Entrovas Tablet 24 mg+26 mg contains a combination of Sacubitril and Valsartan, an advanced medicine used for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). This combination belongs to a class of medicines known as angiotensin receptor neprilysin inhibitors (ARNIs), which help improve heart function, reduce symptoms, and lower the risk of hospitalization and cardiovascular death in patients with heart failure.

Heart failure occurs when the heart becomes unable to pump blood efficiently throughout the body. This leads to symptoms such as shortness of breath, fatigue, swelling of the legs and ankles, and reduced exercise capacity. Entrovas Tablet helps manage these symptoms by improving blood circulation, relaxing blood vessels, and reducing the strain on the heart.

The 24 mg + 26 mg strength is generally used as an initial or starting dose, especially for patients who are new to Sacubitril/Valsartan therapy or those who require a lower dose due to certain medical conditions.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Sacubitril 24 mg

• Valsartan 26 mg

Mechanism of Action

Entrovas Tablet works through the complementary actions of its two active ingredients.

Sacubitril
Sacubitril is a neprilysin inhibitor that blocks the enzyme neprilysin responsible for breaking down beneficial peptides in the body. By inhibiting this enzyme, Sacubitril increases levels of natriuretic peptides, which help:

• Relax and widen blood vessels

• Reduce blood pressure

• Increase sodium and water excretion

• Decrease the workload on the heart

Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that prevents the effects of angiotensin II, a hormone that causes blood vessels to narrow. By blocking this hormone, Valsartan helps:

• Dilate blood vessels

• Lower blood pressure

• Improve blood flow

• Reduce stress on the heart

Together, these actions help improve cardiac efficiency and slow the progression of heart failure.

Indications

Entrovas Tablet 24 mg+26 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)

• Reducing the risk of cardiovascular death in heart failure patients

• Decreasing hospitalization due to worsening heart failure

• Improving symptoms such as shortness of breath, fatigue, and swelling

This lower dose is often prescribed when starting therapy or adjusting treatment.

Dosage and Administration

Dosage should always be determined by a physician based on the patient’s condition.

General recommendations include:

• Usually one tablet twice daily

• May be taken with or without food

• Swallow the tablet whole with water

• If switching from an ACE inhibitor, a 36-hour washout period is required before starting Entrovas

Regular monitoring of blood pressure, kidney function, and potassium levels is recommended during treatment.

Precautions

Before using Entrovas Tablet, inform your doctor if you:

• Have kidney disease or liver impairment

• Have a history of angioedema

• Have low blood pressure

• Are taking potassium supplements or other blood pressure medications

• Are pregnant or planning to become pregnant

This medicine should not be used during pregnancy because it may harm the unborn baby.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Some patients may experience side effects while taking Entrovas Tablet.

Common side effects include:

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Increased potassium levels

• Reduced kidney function

Less common but serious side effects include:

• Angioedema (swelling of face, lips, or throat)

• Severe hypotension

• Kidney impairment

Medical attention should be sought if severe symptoms occur.

Storage

• Store below 25°C in a cool and dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

Entrovas Tablet 24 mg+26 mg provides effective early-stage therapy for heart failure, helping improve heart function, relieve symptoms, and reduce the risk of serious cardiovascular complications.